Astellas Pharma Inc. (OTCMKTS:ALPMY) Shares Shorted: Short Interest Up 519.9% in September

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a significant increase in short interest in September. As of September 30th, there was short interest totaling 155,427 shares, an increase of 519.9% from the September 15th total of 25,074 shares. Based on an average daily trading volume, of 192,822 shares, the short-interest ratio is presently 0.8 days. Currently, 0.0% of the company’s stock are short sold.

Astellas Pharma Stock Performance

ALPMY opened at $14.35 on Monday. The stock has a market cap of $25.97 billion, a PE ratio of 10.92 and a beta of 0.08. The company has a current ratio of 1.20, a quick ratio of 0.93 and a debt-to-equity ratio of 0.16. Astellas Pharma has a 1 year low of $10.03 and a 1 year high of $17.35. The stock’s 50 day simple moving average is $14.72 and its 200-day simple moving average is $14.49.

Analyst Upgrades and Downgrades

Separately, Zacks Research downgraded Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy”.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Japan-based pharmaceutical company that researches, develops, manufactures and commercializes prescription medicines for patients worldwide. Its portfolio focuses on areas of significant unmet medical need, including oncology, immunology, urology, ophthalmology, neuroscience and medical conditions related to genetic regulation.

The company’s products include XTANDI (enzalutamide) for certain prostate cancers, XOSPATA (gilteritinib) for acute myeloid leukemia, PADCEV (enfortumab vedotin-ejfv) for certain urothelial cancers, and PROGRAF (tacrolimus), an immunosuppressant used primarily to help prevent organ rejection following transplantation.